Top

Published in:

Open Access 01-01-2015 | Review Article

Matrix metalloproteinases and genetic mouse models in cancer research: a mini-review

Authors: Edyta Wieczorek, Ewa Jablonska, Wojciech Wasowicz, Edyta Reszka

Published in: Tumor Biology | Issue 1/2015

Abstract

Carcinogenesis is a multistep and also a multifactorial process that involves agents like genetic and environmental factors. Matrix metalloproteinases (MMPs) are major proteolytic enzymes which are involved in cancer cell migration, invasion, and metastasis. Genetic variations in genes encoding the MMPs were shown in human studies to influence cancer risk and phenotypic features of a tumor. The complex role of MMPs seems to be important in the mechanism of carcinogenesis, but it is not well recognized. Rodent studies concentrated particularly on the better understanding of the biological functions of the MMPs and their impact on the pathological process, also through the modification of Mmp genes. This review presents current knowledge and the existing evidence on the importance of selected MMPs in genetic mouse models of cancer and human genetic association studies. Further, this work can be useful for scientists studying the role of the genetic impact of MMPs in carcinogenesis.

Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67.PubMedPubMedCentral

Fink K, Boratynski J. The role of metalloproteinases in modification of extracellular matrix in invasive tumor growth, metastasis and angiogenesis. Postepy Hig Med Dosw. 2012;66:609–28.

Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol. 2003;36:128–37.PubMed

Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980;5751:67–8.

Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 2011;41:271–90.PubMed

Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8:221–33.PubMedPubMedCentral

Overall CM. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol. 2002;22:51–86.PubMed

Foda HD, Zucker S. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today. 2001;6:478–82.PubMed

Lukaszewicz-Zając M, Mroczko B, Szmitkowski M. Gastric cancer—the role of matrix metalloproteinases in tumor progression. Clin Chim Acta. 2011;412:1725–30.PubMed

10.

Said AH, Raufman JP, Xie G. The role of matrix metalloproteinases in colorectal cancer. Cancers (Basel). 2014;6:366–75.

11.

Werner JA, Rathcke IO, Mandic R. The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin Exp Metastasis. 2002;19:275–82.PubMed

12.

Rudolph-Owen LA, Chan R, Muller WJ, Matrisian LM. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res. 1998;58:5500–6.PubMed

13.

Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000;10:415–33.PubMed

14.

Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000;36:1621–30.PubMed

15.

Balbín M, Fueyo A, Tester AM, Pendás AM, Pitiot AS, Astudillo A, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet. 2003;35:252–7.PubMed

16.

Decock J, Thirkettle S, Wagstaff L, Edwards DR. Matrix metalloproteinases: protective roles in cancer. J Cell Mol Med. 2011;15:1254–65.PubMedPubMedCentral

17.

Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci. 2006;11:479–91.PubMed

18.

Noël A, Gutiérrez-Fernández A, Sounni NE, Behrendt N, Maquoi E, Lund IK, et al. New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Front Pharmacol. 2012;3:140.PubMedPubMedCentral

19.

Cheon DJ, Orsulic S. Mouse models of cancer. Annu Rev Pathol. 2011;6:95–119.PubMed

20.

Rodríguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta. 1803;2010:39–54.

21.

Hann B, Balmain A. Building ‘validated’ mouse models of human cancer. Curr Opin Cell Biol. 2001;13:778–84.PubMed

22.

Meuwissen R, Berns A. Mouse models for human lung cancer. Genes Dev. 2005;19:643–64.PubMed

23.

Balmain A. Cancer as a complex genetic trait: tumor susceptibility in humans and mouse models. Cell. 2002;108:145–52.PubMed

24.

Walrath JC, Hawes JJ, Van Dyke T, Reilly KM. Genetically engineered mouse models in cancer research. Adv Cancer Res. 2010;106:113–64.PubMedPubMedCentral

25.

Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010;20:161–8.PubMedPubMedCentral

26.

Becker JC, Houben R, Schrama D, Voigt H, Ugurel S, Reisfeld RA. Mouse models for melanoma: a personal perspective. Exp Dermatol. 2010;19:157–64.PubMed

27.

Fanjul-Fernández M, Folgueras AR, Cabrera S, López-Otín C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta. 1803;2010:3–19.

28.

Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17:1359–70.PubMed

29.

Ding L, Zhao Y, Warren CL, Sullivan R, Eliceiri KW, Shull JD. Association of cellular and molecular responses in the rat mammary gland to 17β-estradiol with susceptibility to mammary cancer. BMC Cancer. 2013;13:573.PubMedPubMedCentral

30.

Son J, Lee JH, Kim HN, Ha H, Lee ZH. cAMP-response-element-binding protein positively regulates breast cancer metastasis and subsequent bone destruction. Biochem Biophys Res Commun. 2010;398:309–14.PubMed

31.

Zhang Y, Davis C, Ryan J, Janney C, Peña MM. Development and characterization of a reliable mouse model of colorectal cancer metastasis to the liver. Clin Exp Metastasis. 2013;30:903–18.PubMed

32.

Akgül B, Pfefferle R, Marcuzzi GP, Zigrino P, Krieg T, Pfister H, et al. Expression of matrix metalloproteinase (MMP)-2, MMP-9, MMP-13, and MT1-MMP in skin tumors of human papillomavirus type 8 transgenic mice. Exp Dermatol. 2006;15:35–42.PubMed

33.

Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997;378:151–60.PubMed

34.

Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008;40:1362–78.PubMed

35.

Westermarck J, Kähäri VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999;13:781–92.PubMed

36.

Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003;253:269–85.PubMed

37.

Rogers MS, D’Amato RJ. The effect of genetic diversity on angiogenesis. Exp Cell Res. 2006;312:561–74.PubMed

38.

Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem. 2001;276:7549–58.PubMed

39.

Tower GB, Coon CC, Benbow U, Vincenti MP, Brinckerhoff CE. Erk 1/2 differentially regulates the expression from the 1G/2G single nucleotide polymorphism in the MMP-1 promoter in melanoma cells. Biochim Biophys Acta Mol Basis Dis. 2002;1586:265–74.

40.

Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett. 2004;208:1–33.PubMed

41.

Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, Buetow K, Fraumeni JF. The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta. 2001;1471:C1–C10.PubMed

42.

Wieczorek E, Wasowicz W, Gromadzinska J, Reszka E. Functional polymorphisms in the matrix metalloproteinase genes and their association with bladder cancer risk and recurrence: a mini-review. Int J Urol 2014;17. doi: 10.1111/iju.12431.

43.

Wieczorek E, Reszka E, Gromadzinska J, Wasowicz W. Neoplasma. 2012;59:237–47.PubMed

44.

Peng B, Cao L, Ma X, Wang W, Wang D, Yu L. Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis. 2010;25:371–9.PubMed

45.

Peng B, Cao L, Wang W, Xian L, Jiang D, Zhao J, et al. Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: a meta-analysis of 50 case–control studies. Mutagenesis. 2010;25:41–8.PubMed

46.

Yang X, Hu JW, Qiu MT, Li M, Yin R, Wang J, et al. Association of matrix metalloproteinase-3–1171(5A>6A) polymorphism with cancer risk: a meta-analysis of 41 studies. PLoS One. 2014;9:e87562.PubMedPubMedCentral

47.

Ji SR, Sun JJ, Li XP, Zhang Y, Liu WF. The association of matrix metalloproteinase-1 genetic polymorphism (−1607 1G >2G) with colorectal cancer: a meta-analysis. Tumor Biol. 2013;34:3801–6.

48.

Hu J, Pan J, Luo ZG. MMP1 rs1799750 single nucleotide polymorphism and lung cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:5981–4.PubMed

49.

Figueroa JD, Ye Y, Siddiq A, Garcia-Closas M, Chatterjee N, Prokunina-Olsson L, et al. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet. 2014;23:1387–98.PubMed

50.

Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M. Genetic susceptibility to breast cancer. Mol Oncol. 2010;4:174–91.PubMed

51.

Ermann J, Glimcher LH. After GWAS: mice to the rescue? Curr Opin Immunol. 2012;24:564–70.PubMedPubMedCentral

52.

Easton DF, Eeles RA. Genome-wide association studies in cancer. Hum Mol Genet. 2008;17:R109–15.PubMed

53.

Lundberg K, Bengtsson C, Kharlamova N, Reed E, Jiang X, Kallberg H, et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Ann Rheum Dis. 2012;72:652–8.PubMed

54.

Ghassibe-Sabbagh M, Platt DE, Youhanna S, Abchee AB, Stewart K, Badro DA, et al. Genetic and environmental influences on total plasma homocysteine and its role in coronary artery disease risk. Atherosclerosis. 2012;222:180–6.PubMed

55.

Sánchez E, de Palma G, Capilla A, Nova E, Pozo T, Castillejo G, et al. Influence of environmental and genetic factors linked to celiac disease risk on infant gut colonization by bacteroides species. Appl Environ Microbiol. 2011;77:5316–23.PubMedPubMedCentral

56.

Lin CW, Yang SF, Chuang CY, Lin HP, Hsin CH. Association of matrix metalloproteinase-11 polymorphisms with susceptibility and clinicopathologic characteristics for oral squamous cell carcinoma. Head Neck. 2014;16. doi: 10.1002/hed.23771.

57.

Srivastava P, Gangwar R, Kapoor R, Mittal RD. Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. Dis Markers. 2010;29:37–46.PubMedPubMedCentral

58.

Tasci AI, Tugcu V, Ozbek E, Ozbay B, Simsek A, Koksal V. A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility. BJU Int. 2008;101:503–7.PubMed

59.

Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, et al. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res. 2006;66:11644–8.PubMed

60.

Srivastava P, Kapoor R, Mittal RD. Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India. Urol Oncol Semin Orig Investig. 2013;31:247–54.

61.

Srivastava P, Mandhani A, Kapoor R, Mittal RD. Role of MMP-3 and MMP-9 and their haplotypes in risk of bladder cancer in North Indian cohort. Ann Surg Oncol. 2010;17:3068–75.PubMed

62.

Wieczorek E, Reszka E, Jablonowski Z, Jablonska E, Krol MB, Grzegorczyk A, et al. Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs), and bladder cancer susceptibility. BJU Int. 2013;112:1207–14.PubMed

63.

Li Y, Sun D, Duan Y, Zhang X, Wang N, Zhou R, et al. Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Mol Biol Rep. 2010;37:197–205.PubMed

64.

Zhang W, Lin H, Zhou Y, Wang Y, Cheng Q. Association of MMP1–1607 (1G>2G) single nucleotide polymorphism with susceptibility to lung cancer in Northwestern Chinese population of Han nationality. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006;23:313–5.PubMed

65.

Wang L, Ma YT, Xie X, Yang YN, Fu ZY, Li XM, et al. Interaction between MMP-9 gene polymorphisms and smoking in relation to myocardial infarction in a Uighur population. Clin Appl Thromb Hemost. 2012;18:72–8.PubMed

66.

Ladiges WC. Mouse models of XRCC1 DNA repair polymorphisms and cancer. Oncogene. 2006;25:1612–9.PubMed

67.

Iyer RP, Patterson NL, Fields GB, Lindsey ML. The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol. 2012;303:H919–30.PubMedPubMedCentral

68.

Witty JP, Lempka T, Coffey RJ, Matrisian LM. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res. 1995;55:1401–6.PubMed

69.

Janssens S, Lijnen HR. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? Cardiovasc Res. 2006;69:585–94.PubMed

70.

Scroyen I, Hemmeryckx B, Lijnen HR. From mice to men: mouse models in obesity research: what can we learn? Thromb Haemost. 2013;109:1–7.

71.

Masson V, de la Ballina LR, Munaut C, Wielockx B, Jost M, Maillard C, et al. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J. 2005;19:234–6.PubMed

72.

Delgado-Enciso I, Cepeda-Lopez FR, Monrroy-Guizar EA, Bautista-Lam JR, Andrade-Soto M, Jonguitud-Olguin G, et al. Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Investig. 2008;65:68–72.

73.

Zhou Y, Yu C, Miao X, Tan W, Liang G, Xiong P, et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis. 2004;25:399–404.PubMed

74.

Beeghly-Fadiel A, Lu W, Long JR, Shu X, Zheng Y, Cai Q, et al. Matrix metalloproteinase-2 polymorphisms and breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 2009;18:1770–6.PubMedPubMedCentral

75.

Roehe AV, Frazzon AP, Agnes G, Damin AP, Hartman AA, Graudenz MS. Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results. Breast Cancer Res Treat. 2007;102:123–4.PubMed

76.

Thiolloy S, Edwards JR, Fingleton B, Rifkin DB, Matrisian LM, Lynch CC. An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment. PLoS One. 2012;7:e29862.PubMedPubMedCentral

77.

Hulboy DL, Gautam S, Fingleton B, Matrisian LM. The influence of matrix metalloproteinase-7 on early mammary tumorigenesis in the multiple intestinal neoplasia mouse. Oncol Rep. 2004;12:13–7.PubMed

78.

Beeghly-Fadiel A, Long JR, Gao YT, Li C, Qu S, Cai Q, et al. Common MMP-7 polymorphisms and breast cancer susceptibility: a multistage study of association and functionality. Cancer Res. 2008;68:6453–9.PubMedPubMedCentral

79.

Thiolloy S, Halpern J, Holt GE, Schwartz HS, Mundy GR, Matrisian LM, et al. Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Res. 2009;69:6747–55.PubMedPubMedCentral

80.

Martin MD, Carter KJ, Jean-Philippe SR, Chang M, Mobashery S, Thiolloy S, et al. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res. 2008;68:6251–9.PubMedPubMedCentral

81.

Ha HY, Moon HB, Nam MS, Lee JW, Ryoo ZY, Lee TH, et al. Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Cancer Res. 2001;61:984–90.PubMed

82.

Biondi ML, Turri O, Leviti S, Seminati R, Cecchini F, Bernini M, et al. MMP1 and MMP3 polymorphisms in promoter regions and cancer. Clin Chem. 2000;46:2023–4.PubMed

83.

Sternlicht MD, Bissell MJ, Werb Z. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene. 2000;19:1102–13.PubMedPubMedCentral

84.

Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, et al. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res. 2002;8:3820–3.PubMed

85.

Andarawewa KL, Motrescu ER, Chenard MP, Gansmuller A, Stoll I, Tomasetto C, et al. Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. Cancer Res. 2005;65:10862–71.PubMed

86.

Andarawewa KL, Boulay A, Masson R, Mathelin C, Stoll I, Tomasetto C, et al. Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res. 2003;63:5844–9.PubMed

87.

Baltazar-Rodriguez LM, Anaya-Ventura A, Andrade-Soto M, Monrroy-Guizar EA, Bautista-Lam JR, Jonguitud-Olguin G, et al. Polymorphism in the matrix metalloproteinase-2 gene promoter is associated with cervical neoplasm risk in Mexican women. Biochem Genet. 2008;46:137–44.PubMed

88.

Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 2004;114:623–33.PubMedPubMedCentral

89.

Ghilardi G, Biondi ML, Mangoni J, Leviti S, DeMonti M, Guagnellini E, et al. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res. 2001;7:2344–6.PubMed

90.

Hinoda Y, Okayama N, Takano N, Fujimura K, Suehiro Y, Hamanaka Y, et al. Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer. 2002;102:526–9.PubMed

91.

Woo M, Park K, Nam J, Kim JC. Clinical implications of matrix metalloproteinase-1,-3,-7,-9,-12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol. 2007;22:1064–70.PubMed

92.

Xu E, Xia X, Lü B, Xing X, Huang Q, Ma Y, et al. Association of matrix metalloproteinase-2 and -9 promoter polymorphisms with colorectal cancer in Chinese. Mol Carcinog. 2007;46:924–9.PubMed

93.

Kitamura T, Fujishita T, Loetscher P, Revesz L, Hashida H, Kizaka-Kondoh S, et al. Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc Natl Acad Sci U S A. 2010;107:13063–8.PubMedPubMedCentral

94.

Kitamura T, Biyajima K, Aoki M, Oshima M, Taketo MM. Matrix metalloproteinase 7 is required for tumor formation, but dispensable for invasion and fibrosis in SMAD4-deficient intestinal adenocarcinomas. Lab Investig. 2009;89:98–105.PubMed

95.

Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A. 1997;94:1402–7.PubMedPubMedCentral

96.

Lièvre A, Milet J, Carayol J, Le Corre D, Milan C, Pariente A, et al. Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. BMC Cancer. 2006;6:270.PubMedPubMedCentral

97.

Garg P, Sarma D, Jeppsson S, Patel NR, Gewirtz AT, Merlin D, et al. Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. Cancer Res. 2010;70:792–801.PubMedPubMedCentral

98.

Masson R, Lefebvre O, Noël A, Fahime ME, Chenard MP, Wendling C, et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol. 1998;140:1535–41.PubMedPubMedCentral

99.

Miao XP, Yu CY, Tan W, Xiong P, Liang G, Lu WF, et al. A functional polymorphism in the matrix metalloproteinase-2 gene promoter (−1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinomal. Cancer Res. 2003;63:3987–90.PubMed

100.

Zhang XM, Miao XP, Xiong P, Yu CY, Tan W, Qu SN, et al. Association of functional polymorphisms in matrix metalloproteinase-2 (MMP-2) and MMP-9 genes with risk of gastric cancer in a Chinese population. Ai Zheng. 2004;23:1233–7.PubMed

101.

Li J, Tian M, Zhao A. Polymorphism in the promoter region of the metalloproteinase-7 increases susceptibility and risk of metastasis of gastric adenocarcinoma. Gastroenterology. 2008;134:A603-A603.

102.

Sugimoto M, Furuta T, Kodaira C, Nishino M, Yamade M, Ikuma M, et al. Polymorphisms of matrix metalloproteinase-7 and chymase are associated with susceptibility to and progression of gastric cancer in Japan. J Gastroenterol. 2008;43:751–61.PubMed

103.

Zhang J, Jin X, Fang S, Wang R, Li Y, Wang N, et al. The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis. 2005;26:1748–53.PubMed

104.

Zinzindohoué F, Blons H, Hans S, Loriot MA, Houllier AM, Brasnu D, et al. Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma. Anticancer Res. 2004;24:2021–6.PubMed

105.

O-charoenrat P, Leksrisakul P, Sangruchi S. A functional polymorphism in the matrix metalloproteinase-1 gene promoter is associated with susceptibility and aggressiveness of head and neck cancer. Int J Cancer. 2006;118:2548–53.PubMed

106.

Hashimoto T, Uchida K, Okayama N, Imate Y, Suehiro Y, Hamanaka Y, et al. Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. Cancer Lett. 2004;211:19–24.PubMed

107.

McCready J, Broaddus WC, Sykes V, Fillmore HL. Association of a single nucleotide polymorphism in the matrix metalloproteinase-1 promoter with glioblastoma. Int J Cancer. 2005;117:781–5.PubMed

108.

Cao ZG, Li CZ. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances oral squamous cell carcinoma susceptibility in a Chinese population. Oral Oncol. 2006;42:32–8.PubMed

109.

Oezgen AG, Karadeniz M, Erdogan M, Berdeli A. Matrix metalloproteinases (MMP)-1, -2, and -9 gene polymorphism in papillary thyroid cancers (PTC). Endocrinologist. 2008;18:137–41.

110.

Shimizu Y, Kondo S, Shirai A, Furukawa M, Yoshizaki T. A single nucleotide polymorphism in the matrix metalloproteinase-1 and interleukin-8 gene promoter predicts poor prognosis in tongue cancer. Auris Nasus Larynx. 2008;35:381–9.PubMed

111.

Lu Z, Cao Y, Wang Y, Zhang Q, Zhang X, Wang S, et al. Polymorphisms in the matrix metalloproteinase-1, 3, and 9 promoters and susceptibility to adult astrocytoma in Northern China. J Neurooncol. 2007;85:65–73.PubMed

112.

Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res. 2004;64:7622–8.PubMed

113.

O-Charoenrat P, Khantapura P. The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol. 2006;42:257–67.PubMed

114.

Zhou G, Zhai Y, Cui Y, Qiu W, Yang H, Zhang X, et al. Functional polymorphisms and haplotypes in the promoter of the MMP2 gene are associated with risk of nasopharyngeal carcinoma. Hum Mutat. 2007;28:1091–7.PubMed

115.

Lu Z, Wang Y, Zhang Q, Zhang X, Wang S, Xie H, et al. Association between the functional polymorphism in the matrix metalloproteinase-7 promoter and susceptibility to adult astrocytoma. Brain Res. 2006;1118:6–12.PubMed

116.

Weng CJ, Chen MK, Lin CW, Chung TT, Yang SF. Single nucleotide polymorphisms and haplotypes of MMP-14 are associated with the risk and pathological development of oral cancer. Ann Surg Oncol. 2012;19:319–27.

117.

Korpi JT, Kervinen V, Mäklin H, Väänänen A, Lahtinen M, Läärä E, et al. Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. Br J Cancer. 2008;98:766–75.PubMedPubMedCentral

118.

Chen TY, Li YC, Liu YF, Tsai CM, Hsieh YH, Lin CW, et al. Role of MMP14 gene polymorphisms in susceptibility and pathological development to hepatocellular carcinoma. Ann Surg Oncol. 2011;18:2348–56.PubMed

119.

Fanjul-Fernández M, Folgueras AR, Fueyo A, Balbín M, Suárez MF, Fernández-García MS, et al. Matrix metalloproteinase Mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses. J Biol Chem. 2013;288:14647–56.PubMedPubMedCentral

120.

Zhu Y, Spitz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 2001;61:7825–9.PubMed

121.

Yu C, Pan K, Xing D, Liang G, Tan W, Zhang L, et al. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res. 2002;62:6430–3.PubMed

122.

Zhou Y, Yu C, Miao X, Wang Y, Tan W, Sun T, et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis. 2005;26:1117–21.PubMed

123.

Acuff HB, Carter KJ, Fingleton B, Gorden DL, Matrisian LM. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Res. 2006;66:259–66.PubMedPubMedCentral

124.

Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998;58:1048–51.PubMed

125.

Gutiérrez-Fernández A, Fueyo A, Folgueras AR, Garabaya C, Pennington CJ, Pilgrim S, et al. Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res. 2008;68:2755–63.PubMed

126.

Itoh T, Tanioka M, Matsuda H, Nishimoto H, Yoshioka T, Suzuki R, et al. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis. 1999;17:177–81.PubMed

127.

Jodele S, Chantrain CF, Blavier L, Lutzko C, Crooks GM, Shimada H, et al. The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res. 2005;65:3200–8.PubMed

128.

Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med. 2009;206:1089–102.PubMedPubMedCentral

129.

Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008;118:1367–79.PubMedPubMedCentral

130.

Li Y, Jin X, Kang S, Wang Y, Du H, Zhang JH, et al. Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol Oncol. 2006;101:92–6.PubMed

131.

Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737–44.PubMedPubMedCentral

132.

Fukuda A, Wang SC, Morris JP, Folias AE, Liou A, Kim GE, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell. 2011;19:441–55.PubMedPubMedCentral

133.

Crawford HC, Scoggins CR, Washington MK, Matrisian LM, Leach SD. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest. 2002;109:1437–44.PubMedPubMedCentral

134.

Krantz SB, Shields MA, Dangi-Garimella S, Cheon EC, Barron MR, Hwang RF, et al. MT1-MMP cooperates with Kras (G12D) to promote pancreatic fibrosis through increased TGF-β signaling. Mol Cancer Res. 2011;9:1294–304.PubMedPubMedCentral

135.

Shchors K, Nozawa H, Xu J, Rostker F, Swigart-Brown L, Evan G, et al. Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis. Oncogene. 2013;32:502–13.PubMed

136.

Littlepage LE, Sternlicht MD, Rougier N, Phillips J, Gallo E, Yu Y, et al. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res. 2010;70:2224–34.PubMedPubMedCentral

137.

Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell. 2005;7:485–96.PubMed

138.

Bruni-Cardoso A, Johnson LC, Vessella RL, Peterson TE, Lynch CC. Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment. Mol Cancer Res. 2010;8:459–70.PubMedPubMedCentral

139.

Hirata H, Naito K, Yoshihiro S, Matsuyama H, Suehiro Y, Hinoda Y. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma. Int J Cancer. 2003;106:372–4.PubMed

140.

Hirata H, Okayama N, Naito K, Inoue R, Yoshihiro S, Matsuyama H, et al. Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP-3 polymorphisms with renal cell carcinoma. Carcinogenesis. 2004;25:2379–84.PubMed

141.

Pendás AM, Folgueras AR, Llano E, Caterina J, Frerard F, Rodríguez F, et al. Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice. Mol Cell Biol. 2004;24:5304–13.PubMedPubMedCentral

142.

Jost M, Folgueras AR, Frérart F, Pendas AM, Blacher S, Houard X, et al. Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice. Cancer Res. 2006;66:5234–41.PubMed

143.

Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103:481–90.PubMedPubMedCentral

144.

Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell. 2008;13:193–205.PubMedPubMedCentral

145.

Konstantinopoulos PA, Karamouzis MV, Papatsoris AG, Papavassiliou AG. Matrix metalloproteinase inhibitors as anticancer agents. Int J Biochem Cell Biol. 2008;40:1156–68.PubMed

146.

Przybylowska K, Zielinska J, Zadrozny M, Krawczyk T, Kulig A, Wozniak P, et al. An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymph node metastasis in breast cancer. J Exp Clin Cancer Res. 2004;23:121–5.PubMed

147.

Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, et al. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat. 2006;95:65–72.PubMed

148.

Hughes S, Agbaje O, Bowen RL, Holliday DL, Shaw JA, Duffy S, et al. Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. Clin Cancer Res. 2007;13:6673–80.PubMed

149.

Decock J, Long JR, Laxton RC, Shu XO, Hodgkinson C, Hendrickx W, et al. Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Res. 2007;67:10214–21.PubMed

150.

Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278:16–27.PubMed

151.

Stojic J, Hagemann C, Haas S, Herbold C, Kuehnel S, Gerngras S, et al. Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci Res. 2008;60:40–9.PubMed

152.

Impola U, Jeskanen L, Ravanti L, Syrjänen S, Baldursson B, Kähäri VM, et al. Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds. Br J Dermatol. 2005;152:720–6.PubMed

153.

Bister VO, Salmela MT, Karjalainen-Lindsberg ML, Uria J, Lohi J, Puolakkainen P, et al. Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer. Dig Dis Sci. 2004;49:653–61.PubMed

Title: Matrix metalloproteinases and genetic mouse models in cancer research: a mini-review
Authors: Edyta Wieczorek
Ewa Jablonska
Wojciech Wasowicz
Edyta Reszka
Publication date: 01-01-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 1/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2747-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Focusing on long noncoding RNA dysregulation in gastric cancer

Genetic variations in monocyte chemoattractant protein-1 and susceptibility to ovarian cancer

Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study

Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems

Hsp27 (HSPB1) differential expression in normal salivary glands and pleomorphic adenomas and association with an increased Bcl2/Bax ratio

Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small-cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival

Keynote webinar | Spotlight on antibody–drug conjugates in cancer